Published in J Virol on April 01, 2003
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol (2006) 3.75
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep (2003) 3.29
CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A (2004) 3.01
West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol (2006) 2.79
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol (2006) 2.55
Characterization of functional hepatitis C virus envelope glycoproteins. J Virol (2004) 2.40
Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol (2010) 2.38
CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2004) 2.38
Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol (2004) 2.26
The C-type lectin receptors CLEC-2 and Dectin-1, but not DC-SIGN, signal via a novel YXXL-dependent signaling cascade. J Biol Chem (2007) 2.24
L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci U S A (2003) 2.21
Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol (2005) 2.19
CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol (2008) 2.09
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
Living in the liver: hepatic infections. Nat Rev Immunol (2012) 2.03
N-linked glycosylation of west nile virus envelope proteins influences particle assembly and infectivity. J Virol (2005) 2.00
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol (2004) 1.98
DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.92
DC-SIGN and L-SIGN can act as attachment receptors for alphaviruses and distinguish between mosquito cell- and mammalian cell-derived viruses. J Virol (2003) 1.91
The cell biology of receptor-mediated virus entry. J Cell Biol (2011) 1.75
Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon. J Virol (2005) 1.72
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol (2005) 1.53
Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells. PLoS One (2011) 1.52
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic cells. J Cell Biol (2004) 1.48
L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc Natl Acad Sci U S A (2004) 1.48
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog (2010) 1.45
CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J Virol (2003) 1.38
Lentivirus-mediated RNA interference of DC-SIGN expression inhibits human immunodeficiency virus transmission from dendritic cells to T cells. J Virol (2004) 1.37
Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J Virol (2007) 1.34
Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J Clin Invest (2005) 1.34
DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J Virol (2006) 1.31
Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol (2006) 1.29
Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol (2012) 1.28
Hepatitis C virus proteins. World J Gastroenterol (2007) 1.28
High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol (2004) 1.25
Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding. Virol J (2008) 1.21
Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry. J Virol (2005) 1.21
Tetraspanins in viral infections: a fundamental role in viral biology? J Virol (2005) 1.16
Recombinant extracellular domains of tetraspanin proteins are potent inhibitors of the infection of macrophages by human immunodeficiency virus type 1. J Virol (2006) 1.15
Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J Virol (2009) 1.14
CD209 genetic polymorphism and tuberculosis disease. PLoS One (2008) 1.14
Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J Virol (2005) 1.14
Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J Virol (2008) 1.11
Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. J Virol (2004) 1.06
Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro. PLoS One (2009) 1.05
Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles. Am J Pathol (2006) 1.04
DC-SIGN neck domain is a pH-sensor controlling oligomerization: SAXS and hydrodynamic studies of extracellular domain. J Biol Chem (2009) 1.02
Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes. J Virol (2013) 1.02
Poly(I:C) and lipopolysaccharide innate sensing functions of circulating human myeloid dendritic cells are affected in vivo in hepatitis C virus-infected patients. J Virol (2007) 1.00
Liver immunology. Compr Physiol (2013) 0.99
Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J Virol (2004) 0.99
Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. J Virol (2006) 0.98
Synthesis, assembly, and processing of the Env ERVWE1/syncytin human endogenous retroviral envelope. J Virol (2005) 0.96
A look behind closed doors: interaction of persistent viruses with dendritic cells. Nat Rev Microbiol (2010) 0.96
Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entry. J Biomed Sci (2009) 0.92
Barriers of hepatitis C virus interspecies transmission. Virology (2013) 0.92
Transmission of human hepatitis C virus from patients in secondary cells for long term culture. Virol J (2005) 0.92
The impact of hepatitis C virus entry on viral tropism. Cell Host Microbe (2014) 0.92
Sequencing of DC-SIGN promoter indicates an association between promoter variation and risk of nasopharyngeal carcinoma in cantonese. BMC Med Genet (2010) 0.89
An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol (2013) 0.87
Influence of dendritic cells on viral pathogenicity. PLoS Pathog (2009) 0.87
Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. J Virol (2014) 0.87
Immunological functions of liver sinusoidal endothelial cells. Cell Mol Immunol (2016) 0.86
Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front Biosci (Landmark Ed) (2009) 0.86
Dengue virus entry as target for antiviral therapy. J Trop Med (2012) 0.86
How hepatitis C virus invades hepatocytes: the mystery of viral entry. World J Gastroenterol (2014) 0.85
Induction of hepatitis C virus-specific cytotoxic T and B cell responses by dendritic cells expressing a modified antigen targeting receptor. World J Gastroenterol (2005) 0.84
Virological analysis and phenotypic characterization of peripheral blood lymphocytes of hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. Clin Exp Immunol (2006) 0.83
DC-SIGN: binding receptor for HCV? World J Gastroenterol (2004) 0.83
Binding of DC-SIGN to the hemagglutinin of influenza A viruses supports virus replication in DC-SIGN expressing cells. PLoS One (2013) 0.83
The role of cellular adhesion molecules in virus attachment and entry. Philos Trans R Soc Lond B Biol Sci (2015) 0.83
Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA. Mol Pharm (2013) 0.82
Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus. J Virol (2006) 0.82
Positive selection of HIV host factors and the evolution of lentivirus genes. BMC Evol Biol (2010) 0.82
Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection. J Biomed Biotechnol (2010) 0.82
Analysis of a conserved RGE/RGD motif in HCV E2 in mediating entry. Virol J (2009) 0.81
Autophagy in hepatitis C virus-host interactions: potential roles and therapeutic targets for liver-associated diseases. World J Gastroenterol (2014) 0.80
Utilization of human DC-SIGN and L-SIGN for entry and infection of host cells by the New World arenavirus, Junín virus. Biochem Biophys Res Commun (2013) 0.80
Impairment of TLR7-dependent signaling in dendritic cells from chronic hepatitis C virus (HCV)-infected non-responders to interferon/ribavirin therapy. J Clin Immunol (2010) 0.80
Protein interactions during the flavivirus and hepacivirus life cycle. Mol Cell Proteomics (2017) 0.79
Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle? Virology (Auckl) (2013) 0.79
Characterization of the Bas-Congo virus glycoprotein and its function in pseudotyped viruses. J Virol (2013) 0.79
Expression of the C-type lectins DC-SIGN or L-SIGN alters host cell susceptibility for the avian coronavirus, infectious bronchitis virus. Vet Microbiol (2012) 0.79
ERK signaling is triggered by hepatitis C virus E2 protein through DC-SIGN. Cell Stress Chaperones (2013) 0.78
AM3 modulates dendritic cell pathogen recognition capabilities by targeting DC-SIGN. Antimicrob Agents Chemother (2007) 0.78
Role of homozygous DC-SIGNR 5/5 tandem repeat polymorphism in HIV-1 exposed seronegative North Indian individuals. J Clin Immunol (2007) 0.78
Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am (2015) 0.77
Human herpesvirus 8 glycoprotein B binds the entry receptor DC-SIGN. Virus Res (2014) 0.77
Association of Neisseria gonorrhoeae Opa(CEA) with dendritic cells suppresses their ability to elicit an HIV-1-specific T cell memory response. PLoS One (2013) 0.77
The missing pieces of the HCV entry puzzle. Future Virol (2015) 0.76
Gumming up the works: DNA polymers as HCV entry inhibitors. Gastroenterology (2009) 0.76
Dendritic cells: The warriors upfront-turned defunct in chronic hepatitis C infection. World J Hepatol (2015) 0.75
Dominating expression of negative regulatory factors downmodulates major histocompatibility complex Class-II expression on dendritic cells in chronic hepatitis C infection. World J Gastroenterol (2016) 0.75
Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene (1991) 38.64
Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature (1981) 24.17
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell (2000) 14.43
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology (1995) 14.30
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol (2000) 8.62
Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science (1997) 7.53
Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A (1999) 6.05
Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science (1992) 5.61
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol (1999) 4.99
Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol (2002) 4.63
DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity (2002) 4.62
Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol (2002) 4.55
C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol (2002) 4.47
Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science (2001) 4.23
CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol (1998) 4.01
Role for adenosine triphosphate in regulating the assembly and transport of vesicular stomatitis virus G protein trimers. J Cell Biol (1987) 3.84
The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol (2002) 3.48
A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A (1996) 3.25
DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology (2003) 3.20
A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J Virol (1998) 3.13
A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J Biol Chem (2001) 3.08
Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1992) 3.02
DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus. J Virol (2001) 2.95
Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol (2002) 2.93
Formation of native hepatitis C virus glycoprotein complexes. J Virol (1997) 2.87
DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci U S A (2001) 2.86
HIV-1 membrane fusion: targets of opportunity. J Cell Biol (2000) 2.84
Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol (1998) 2.71
Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med (2002) 2.68
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med (2002) 2.64
Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol (2002) 2.53
cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor. J Virol (2001) 2.50
Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol (2000) 2.50
Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology (2001) 2.49
Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J Virol (2002) 2.46
Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol (1999) 2.44
Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol (2003) 2.42
Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol (1999) 2.26
Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood (2001) 2.26
Biogenesis of hepatitis C virus envelope glycoproteins. J Gen Virol (2001) 2.19
Characterization of pseudotype VSV possessing HCV envelope proteins. Virology (2001) 2.15
Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. J Biol Chem (1998) 2.14
Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. J Virol (1998) 2.09
Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission. J Virol (2002) 1.99
In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood (1998) 1.98
Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. J Viral Hepat (1996) 1.94
Evidence from studies with a cross-linking reagent that the haemagglutinin of influenza virus is a trimer. Virology (1977) 1.93
Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol (2003) 1.89
Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol (2002) 1.84
Quantitative expression and virus transmission analysis of DC-SIGN on monocyte-derived dendritic cells. J Virol (2002) 1.78
Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology (2002) 1.67
Molecular characterization of two novel C-type lectin-like receptors, one of which is selectively expressed in human dendritic cells. Eur J Immunol (2000) 1.67
Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol (2001) 1.67
Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol (2002) 1.61
Placental expression of DC-SIGN may mediate intrauterine vertical transmission of HIV. J Pathol (2001) 1.58
Cell fusion activity of hepatitis C virus envelope proteins. J Virol (2000) 1.50
Interactions between PE2, E1, and 6K required for assembly of alphaviruses studied with chimeric viruses. J Virol (1996) 1.33
Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol (2000) 1.17
The C-terminal region of the hepatitis C virus E1 glycoprotein confers localization within the endoplasmic reticulum. J Gen Virol (1999) 1.15
The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood (2001) 1.13
Endocytosis via galactose receptors in vivo. Ligand size directs uptake by hepatocytes and/or liver macrophages. Exp Cell Res (1986) 1.10
Hepatitis C virus and mixed cryoglobulinaemia. Eur J Clin Invest (1993) 1.09
Endothelial cell-mediated uptake of a hepatitis B virus: a new concept of liver targeting of hepatotropic microorganisms. Hepatology (2001) 1.07
Hepatitis C virus infection in type II mixed cryoglobulinemia. Arthritis Rheum (1993) 0.92
Dendritic cells and chronic hepatitis virus carriers. Intervirology (2001) 0.92
The role of liver endothelium in the binding and uptake of ceruloplasmin: studies with colloidal gold probe. J Ultrastruct Res (1985) 0.90
Binding, uptake, and transcytosis of ligands for mannose-specific receptors in rat liver: an electron microscopic study. Exp Cell Res (1988) 0.86
Extrahepatic manifestations of hepatitis C virus infection. Ann Intern Med (1996) 0.80
Endothelial transcytosis of iron-transferrin in the liver does not involve endosomal traffic. Pathobiology (1992) 0.80
The role of endosomal traffic in the transendothelial transport of ceruloplasmin in the liver. Biochem Biophys Res Commun (1989) 0.79
Immune complexes in hepatitis C. Hepatology (1997) 0.78
Lymphoproliferative diseases and hepatitis C virus infection. Ann Med Interne (Paris) (2000) 0.78
A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A (2004) 44.81
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
A diverse range of gene products are effectors of the type I interferon antiviral response. Nature (2011) 12.86
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Suppression of inflammation by a synthetic histone mimic. Nature (2010) 8.80
Replication of hepatitis C virus. Nat Rev Microbiol (2007) 8.31
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 6.16
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell (2009) 5.74
Analyses of pig genomes provide insight into porcine demography and evolution. Nature (2012) 5.58
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Unravelling hepatitis C virus replication from genome to function. Nature (2005) 5.25
HCV persistence and immune evasion in the absence of memory T cell help. Science (2003) 5.23
Lanthanide-transition-metal sandwich framework comprising {Cu3} cluster pillars and layered networks of {Er36} wheels. Angew Chem Int Ed Engl (2005) 4.93
DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med (2003) 4.69
Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol (2002) 4.63
Unsupervised learning of an atlas from unlabeled point-sets. IEEE Trans Pattern Anal Mach Intell (2004) 4.63
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A (2002) 4.48
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Molecular biology of flaviviruses. Adv Virus Res (2003) 4.39
Cross-leg flaps: our preferred alternative to free flaps in the treatment of complex traumatic lower extremity wounds. J Am Coll Surg (2013) 4.30
Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol (2007) 4.28
ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell (2011) 4.26
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology (2014) 4.15
Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature (2007) 4.12
A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum (2012) 4.01
Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med (2009) 3.97
Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature (2013) 3.93
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84
Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature (2005) 3.83
Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature (2003) 3.72
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Recognizing names in biomedical texts: a machine learning approach. Bioinformatics (2004) 3.70
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
Expression analysis of G Protein-Coupled Receptors in mouse macrophages. Immunome Res (2008) 3.54
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 3.47
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol (2010) 3.44
Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol (2011) 3.44
Genomic analyses identify distinct patterns of selection in domesticated pigs and Tibetan wild boars. Nat Genet (2013) 3.41
The changing face of HIV in China. Nature (2008) 3.39
Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol (2004) 3.39
Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature (2013) 3.39
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci U S A (2002) 3.21
DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology (2003) 3.20
Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J Virol (2003) 3.19
The phosphothreonine lyase activity of a bacterial type III effector family. Science (2007) 3.18
The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem (2004) 3.15
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J Virol (2002) 3.07
Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation. Proc Natl Acad Sci U S A (2007) 3.06
Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol (2002) 3.06
Dorsal root ganglion neurons innervating skeletal muscle respond to physiological combinations of protons, ATP, and lactate mediated by ASIC, P2X, and TRPV1. J Neurophysiol (2008) 2.99
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol (2012) 2.98
Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol (2002) 2.93
Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology (2008) 2.91
Pseudomonas syringae effector AvrPto blocks innate immunity by targeting receptor kinases. Curr Biol (2007) 2.84
Porous lanthanide-organic open frameworks with helical tubes constructed from interweaving triple-helical and double-helical chains. Angew Chem Int Ed Engl (2005) 2.83
Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg (2008) 2.79
West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol (2006) 2.79
Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci U S A (2004) 2.77
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol (2009) 2.68
Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol (2007) 2.65
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 2.63
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature (2006) 2.58
Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe (2009) 2.58
Roles of nonstructural protein nsP2 and Alpha/Beta interferons in determining the outcome of Sindbis virus infection. J Virol (2002) 2.55
Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med (2006) 2.53
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51
Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum (2009) 2.50
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 2.49
Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog (2010) 2.48
Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J Virol (2002) 2.46